



SyrSpend[®] SF

Table de compatibilité

SyrSpend® SF
PH4 (liquid)



SyrSpend® SF
PH4 NEO (dry)



SyrSpend® SF
PH4 (dry)



SyrSpend® SF
ALKA (dry)



Principes actifs (API)	Concentration	Stabilité physico-chimique (jours)	Conservation	Stabilité physico-chimique (jours)	Stabilité physico-chimique (jours)	Conservation
Acetazolamide ²¹	25 mg/mL	90				
Acide Folique ¹⁷	1 mg/mL	90				
Acide ursodésoxycholique (ursodiol) ^{13, 28}	20 mg/mL	90				
	30 mg/mL	66				
Allopurinol ¹⁶	20 mg/mL	90				
Alprazolam ²⁰	1 mg/mL	90				
Amiodarone HCl ¹	5 mg/mL	90				
Amitriptyline HCl ¹⁶	10 mg/mL	90				
Amlodipine (besylate) ²	1 mg/mL	90				
Atenolol ³	1 mg/mL	60				
	5 mg/mL	90				
Atropine sulfate ²⁰	0.1 mg/mL	90				
Azathioprine ²⁹	50 mg/mL	14				
Baclofène ^{21, 28}	2 mg/mL	90				
	10 mg/mL	90				
Caféine ¹⁷	10 mg/mL	90				
Captopril ⁴	0.8 mg/mL	14				
Carbamazepine ¹⁶	25 mg/mL	90				
Carvedilol ^{16, 28}	1 mg/mL	90				
	5 mg/mL	90				
Celecoxib (capsules) ²²	10 mg/mL	90				
Chloral hydrate ²²	100 mg/mL	60				
Chloroquine phosphate ²	15 mg/mL	90				
Cholecalciferol (vit. D3) ⁵	50,000 IU/mL	90				
Ciclosporine ²²	100 mg/mL	90				
Ciprofloxacin HCl ²²	50 mg/mL	90 / 60				
Clomipramine HCl ¹⁷	5 mg/mL	90				
Clonazepam ³	0.2 mg/mL	90				
Clonidine HCl ²⁹	0.1 mg/mL	90				
Clopidogrel (bisulfate, comprimés) ²⁹	5 mg/mL	30				
Cloxacilline (gélules)*, 23	50 mg/mL	5				
Clozapine comprimés	25 mg/mL	90 / 60				
Cyanocobalamine (vit. B12)	0.2 mg/mL	90				
Dapsone ²	2 mg/mL	90				
Darunavir & cobicistat (comprimés)*, 30	20 / 3.75 mg/mL	7				

Compatible combination

Combination not recommended

Storage temperature

**SyrSpend® SF
PH4 (liquid)
(PRESERVED)**

**SyrSpend® SF
PH4 NEO (dry)
(PRESERVED)**

**SyrSpend® SF
PH4 (dry)
(UNPRESERVED)**

**SyrSpend® SF
ALKA (dry)
(UNPRESERVED)**



Principes actifs (API)	Concentration	Stabilité physico-chimique (jours)	Conservation	Stabilité physico-chimique (jours)	Stabilité physico-chimique (jours)	Conservation
Dexamethasone ³	1 mg/mL	90				
Diclofenac sodium ³	5 mg/mL	90				
Diltiazem HCl ³	12 mg/mL	90				
Dipyridamole ²¹	10 mg/mL	90				
Domperidone ¹⁶	5 mg/mL	90				
Enalapril maleate ³	1 mg/mL	90				
Esomeprazole magnesium ^{**} , ¹⁸	3 mg/mL				60	
Ethambutol 2 HCl ^{**} (comprimés) ²⁹	50 mg/mL	30				
Ethambutol 2 HCl ^{**} , ²⁹	50 mg/mL	90				
	100 mg/mL	90				
Flecainide acetate (comprimés) ²²	20 mg/mL	90				
Furosemide ¹	10 mg/mL				14	
Gabapentine ⁵	50 mg/mL	90				
Glutamine ²⁰	250 mg/mL	90				
Glycopyrrolate (glycopyrronium bromide) ²²	0.5 mg/mL	90				
Griseofulvin ²⁹	25 mg/mL	90				
Haloperidol ⁵	0.5 mg/mL	90				
Hydralazine HCl ²⁹	4 mg/mL	30				
Hydrochlorothiazide ¹⁷ , ²⁸	2 mg/mL	90				
	5 mg/mL	90				
Hydrocortisone ²²	1 mg/mL	90				
Hydrocortisone hemisuccinate ¹	2 mg/mL	60				
Hydrocortisone sodium phosphate ¹	2 mg/mL	60				
Hydroxychloroquine sulfate ^{***}	25 mg/mL	85				
	50 mg/mL	85				
Imipramine HCl ⁵	5 mg/mL	90				
Isoniazide ¹⁶	10 mg/mL	90				
Itraconazole ²²	20 mg/mL	90				
Ketoconazole ¹⁶	20 mg/mL	90				
Kétoprofène ³	20 mg/mL	90				
Labetalol HCl (comprimés) ²²	40 mg/mL	90				
Lamotrigine ³	1 mg/mL	90				
Lansoprazole ¹⁸	2 mg/mL					
Levodopa et carbidopa ⁵	5 / 1.25 mg/mL	60 / 30				
Lévofloxacine ²⁰	50 mg/mL	90				
Lisinopril (as dihydrate) ¹⁶	1 mg/mL	90				

Compatible combination

Combination not recommended

Storage temperature

**SyrSpend® SF
PH4 (liquid)
(PRESERVED)**



**SyrSpend® SF
PH4 NEO (dry)
(PRESERVED)**



**SyrSpend® SF
PH4 (dry)
(UNPRESERVED)**



**SyrSpend® SF
ALKA (dry)
(UNPRESERVED)**



Principes actifs (API)	Concentration	Stabilité physico-chimique (jours)	Conservation	Stabilité physico-chimique (jours)	Stabilité physico-chimique (jours)	Conservation
Loperamide HCl ¹⁷	1 mg/mL	90				
Lorazepam ⁵	1 mg/mL	90 / 60				
Mebeverine HCl ²¹	10 mg/mL	90				
Mélatonine ²²	3 mg/mL	90				
Mercaptopurine (comprimés) ²⁸	10 mg/mL	90				
Methadone HCl ²⁸	10 mg/mL	90				
Methotrexate ¹⁷	2.5 mg/mL	90				
Metoprolol tartrate ²⁰	10 mg/mL	90				
Metronidazole benzoate ⁷	80 mg/mL	90				
Midazolam (HCl, injection fluid) ^{8, 19}	1 mg/mL	60				
Minocycline HCl ⁵	10 mg/mL	60				
Nadolol ¹⁷	10 mg/mL	90				
Naltrexone HCl ¹⁷	1 mg/mL	90				
Naproxène ¹⁶	25 mg/mL	90				
Nifedipine ¹	4 mg/mL	90				
Nitrendipine (comprimés)*. ²⁴	5 mg/mL	60				
Nitrofurantoin****. ^{20, 29}	2 mg/mL	90				
	10 mg/mL	90				
Omeprazole**. ^{9, 18}	2 mg/mL				60	
	5 mg/mL				60	
Ondansetron HCl	0.8 mg/mL	90				
Oseltamivir (phosphate, capsules) ^{10, 19, 28}	6 mg/mL	90				
	15 mg/mL	90				
Oxandrolone ²⁰	3 mg/mL	90				
Pantoprazole sodium**. ¹⁸	3 mg/mL				60	
Paracetamol (acetaminophen) ¹⁶	50 mg/mL	90				
Penicillamine ³	50 mg/mL	90				
Pentoxifylline ¹⁷	20 mg/mL	90				
Phenobarbital ^{1, 28}	9 mg/mL	90				
	15 mg/mL	90				
Phénytoïne ²	15 mg/mL	90				
Prednisone*. ²⁵	5 mg/mL	60				
Prednisolone sodium phosphate ¹	1.5 mg/mL	30				
Prégabaline ²⁰	20 mg/mL	90				

Compatible combination

Combination not recommended

Storage temperature

**SyrSpend® SF
PH4 (liquid)
(PRESERVED)**



**SyrSpend® SF
PH4 NEO (dry)
(PRESERVED)**



**SyrSpend® SF
PH4 (dry)
(UNPRESERVED)**



**SyrSpend® SF
ALKA (dry)
(UNPRESERVED)**



Principes actifs (API)	Concentration	Stabilité physico-chimique (jours)	Conservation	Stabilité physico-chimique (jours)	Stabilité physico-chimique (jours)	Conservation
Propranolol HCl ^{11, 19, 28}	0.5 mg/mL	90				
	1 mg/mL	90				
	5 mg/mL	90				
Propylthiouracile ²¹	5 mg/mL	90				
Pyrazinamide* ^{26, 28}	100 mg/mL	90				
Pyridoxine HCl (vit. B6) ²	50 mg/mL	90				
Quinidine sulfate ²¹	10 mg/mL	90				
Rabeprazole ¹⁸	3 mg/mL					
Ranitidine HCl ¹	14 mg/mL	58 / 36				
Riboflavin (vit. B2) ²⁰	10 mg/mL	90				
Rifampicine ¹²	25 mg/mL	60				
Sertraline HCl ¹⁶	10 mg/mL	90				
Sildenafil citrate	2.5 mg/mL	90				
Simvastatine ¹	1 mg/mL	90				
Sotalol HCl (comprimés) ²⁸	5 mg/mL	90				
	2.0 mg/mL	90				
	2.5 mg/mL	90				
Spironolactone et hydrochlorothiazide ²²	5/5 mg/mL	90				
	5/5 mg/mL	90				
Sulfadiazine ²	100 mg/mL	90				
Sulfasalazine ²	100 mg/mL	90				
Tacrolimus (monohydrate) ^{5, 28}	0.5 mg/mL	90				
	1 mg/mL	90				
Terbinafine HCl ⁵	25 mg/mL	90				
Tetracycline HCl ²	25 mg/mL	90				
Thiamine HCl (vit. B1) ³	100 mg/mL	90				
Thioguanine ²⁹	2.5 mg/mL	90				
Tiagabine HCl (comprimés) ²²	1 mg/mL	90 / 30				
Topiramate ²¹	5 mg/mL	90				
Tramadol HCl ⁵	10 mg/mL	90				
Triméthoprime ²	10 mg/mL	90				
Valsartan ⁵	4 mg/mL	90				
Vancomycin HCl ^{14, 28}	25 mg/mL	90				
	50 mg/mL	90				
Verapamil HCl ¹⁵	50 mg/mL	60				
Warfarine sodium (comprimés)* ²⁷	1 mg/mL	44 / 10				

Compatible combination

Combination not recommended

2-8 °C

15-25 °C

Storage temperature

- * Study performed by independent scientific working groups without Fagron supervision. For a full list of all references, please be referred to: www.fagron.com/en/external-study-overview.
- ** Use raw pharmaceutical material for the API when compounding.
- *** Based on accelerated stability data. Real-time study is ongoing.
- **** Higher concentrations can thicken over time. If higher concentrations are needed, please assure the suspension keeps sufficiently thin to handle. For all nitrofurantoin compounds in SyrSpend® SF, please consult Fagron Compounding Matters for the compounding instructions

References

1. Geiger CM, Sorenson B, Whaley P. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. *Int J Pharm Compd.* 2015;19:420-7.
2. Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MA, Raposo NR. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. *J Pharm Biomed Anal* 2016;118:105-112.
3. Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D and Thiamine in SyrSpend SF PH4 Oral Suspensions. *Int J Pharm Compd.* 2016;20:167-174.
4. Geiger CM, Sorenson B, Whaley PA. Stability of Captopril in SyrSpend SF. *Int J Pharm Compd.* 2013;17:336-338.
5. Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride, valsartan in SyrSpend® SF PH4 oral suspensions. *Pharmazie.* 2016;71:185-91.
6. Sorenson B, Voudrie MA, Gehrig D. Stability of Gabapentin in SyrSpend SF. *Int J Pharm Compd.* 2012;16:347-349.
7. Vu NT, Aloumanis V, Ben MJ, Kupiec TC, Patterson EK, Radke J, Erickson MA, Schneider G. Stability of Metronidazole Benzoate in SyrSpend SF One-step Suspension System. *Int J Pharm Compd.* 2008;12:558-564.
8. Geiger CM, Sorenson B, Whaley PA. Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry. *Int J Pharm Compd.* 2013;17:344-346.
9. Whaley PA, Voudrie MA, Sorenson B. Stability of Omeprazole in SyrSpend SF Alka (Reconstituted). *Int J Pharm Compd.* 2012;16:164-166.
10. Voudrie MA, Allen B. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup and SyrSpend SF (For Reconstitution). *Int J Pharm Compd.* 2010;14:82-85.
11. Geiger CM, Voudrie MA, Sorensen B. Stability of Propranolol Hydrochloride in SyrSpend SF. *Int J Pharm Compd.* 2012;16:513-515.
12. Sorenson B, Whaley P. Stability of Rifampin in SyrSpend SF. *Int J Pharm Compd.* 2013;17:162-164.
13. Geiger CM, Voudrie MA, Sorenson B. Stability of Ursodiol in SyrSpend SF Cherry Flavored. *Int J Pharm Compd.* 2012;16:510-512.
14. Whaley PA, Voudrie MA. Stability of Vancomycin in SyrSpend SF. *Int J Pharm Compd.* 2012;16:167-169.
15. Voudrie MA, Alexander B, Allen B. Stability of Verapamil Hydrochloride in SyrSpend SF compared to Sorbitol containing syrup and suspending vehicles. *Int J Pharm Compd.* 2011;15:255-258.
16. Polonini HC, Loures S, de Araujo ED, Brandão MAF and Ferreira AO. Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. *Int J Pharm Compd.* 2016;20:426-434.
17. Polonini HC, Silva SL, de Almeida TR, Brandão MAF and Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. *Eur J Hosp Pharm.* 2016 (Published Online First).
18. Polonini HC, Silva SL, Loures S, Almy R, Balland A, Brandão MAF and Ferreira AO. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle. *Eur J Hosp Pharm* 2016;0:1-7.
19. Dijkers ECF, Nanhekhan V, Thorissen A. Updated Stability Data of Midazolam, Oseltamivir Phosphate, and Propranolol Hydrochloride in SyrSpend SF and Minoxidil in Espumil. *Int J Pharm Compd.* 2017;21:240-241.
20. Ferreira AO, Polonini HC, Loures da Silva S, Cerqueira de Melo VA, de Andrade L and Brandão MAF. Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabalin, and Riboflavin in SyrSpend SF pH4 Oral Suspensions. *Int J Pharm Compd.* 2017;21:255-263.
21. Polonini HC, Loures da Silva S, Buzinari Aglio NC, Abreu J, Brandão MAF and Ferreira AO. Stability of Acetazolamide, Baclofen, Dipyrindamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4. *Int J Pharm Compd.* 2017;21:339-346.
22. Uriel M, Gómez-Rincón C, Marro, D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. *Die Pharmazie.* 2018; 73:196-201.
23. Barbazan C, Le Daré B, Lester MA and Boivin PN. Etude de stabilité d'une suspension buvable de cloxacilline à usage pédiatrique. Poster presentation at 11th Rencontres Convergences Santé Hôpital 2016.
24. Bellay R, Lesourd F, Quilliec C, Gicquel T, Boivin PN and Lester MA. Stabilité d'une suspension buvable de nitrendipine 5 mg/mL. Poster presentation at 11th Rencontres Convergences Santé Hôpital 2016.
25. Bonnaure AC, Bellay R, Rault P, Lester MA and Boivin PN. Stability study of 5 mg/ml pediatric prednisone oral suspension in SyrSpend®. 20th European GERPAC Conference 2017.
26. Boivin P, Geffroy C, Tron C, et al PP-054 Stability study of 100 mg/ml paediatric pyrazinamide oral suspension in syrSpend. *Eur J Hosp Pharm* 2017;24:A225.
27. Guillois G, Fetique L, Perovic I, et al PP-028 Stability study of 1 mg/ml paediatric warfarin oral suspension in syrSpend. *Eur J Hosp Pharm* 2017;24:A214.
28. Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. *Int J Pharm Compd.* 2018 Nov-Dec;22(6):516-526.
29. Polonini H, da Silva SL, de Araújo EP, Ferreira AO, Anagnostou K, Dijkers ECF. Stability of Azathioprine, Clonidine hydrochloride, Clopidogrel bisulfate, Ethambutol hydrochloride, Griseofulvin, Hydralazine hydrochloride, Nitrofurantoin and Thioguanine oral suspensions compounded with SyrSpend® SF PH4. *Int J Pharm Compd.* 2020 May-June;24(3):252-262.
30. Zanon D, Manca A, De Nicolò A, et al. Data on the stability of darunavir/cobicistat suspension after tablet manipulation [published online ahead of print, 2020 Apr 12]. *Data Brief.* 2020;30:105552.

Disclaimer

Disclaimer: While a great deal of effort has been made to ensure the accuracy of the information contained herein, no claims are made as to the uses, safety, efficacy, or bioavailability of these recommendations. The information cannot be construed as (medical) advice, recommendation, or opinion. Health professionals using this information are advised to do so solely if appropriate in their own professional opinion and judgment. Fagron does not accept and cannot be held responsible or liable in any case for the information contained herein.



Fagron SAS

37, rue Hélène Muller, Bât. D2
94320 Thiais
France

T : +33 (0)1 48 90 17 29
F : +33 (0)810 064 187
www.fagron.fr

 **Fagron**
personalizing
medicine